U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07621159) titled 'A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer' on May 27.
Brief Summary: This is a phase Ib/II clinical study. All participants are patients with advanced colorectal cancer (CRC). The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary anti-tumor efficacy of HDM2017 in combination with standard of care in patients with advanced CRC.
Study Start Date: July 15
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer Metastatic
Intervention:
DRUG: HDM2017
Following a predefined dose and date.
DRUG: Fruquintinib
Foll...